Previous 10 |
Liminal BioSciences, Inc. (LMNL) Q4 2020 Earnings Conference Call March 25, 2021, 08:30 ET Company Participants Shrinal Inamdar - Investor Relations and Communications Manager Bruce Pritchard - CEO Patrick Sartore - President Murielle Lortie - CFO Conference Call Participants Yasmeen Rahimi -...
Liminal BioSciences (LMNL): FY Net loss of $122.1M.Revenue of $3.3M (-32.7% Y/Y) beats by $0.6M.Cash and cash equivalents at December 31, 2020 were $45.1 million. The Company's working capital, i.e., the current assets net of current liabilities, at December 31, 2020 amounted to $49.2 million...
Liminal BioSciences Reports Fourth Quarter and Year End 2020 Financial Results PR Newswire Initiated Phase 1 Multiple Ascending Dose Clinical Trial of Fezagepras OXER1 Antagonist Preclinical R&D Program Acquired Changes to Board of Directors &...
A new study has found that patients with COVID-19 given convalescent plasma did not show a survival benefit compared to those on standard of care.The study, which has yet to be peer reviewed, found that there was no difference in 28-day mortality between the two groups.Results also showed tha...
The National Institutes of Health has halted a clinical trial evaluating the safety and effectiveness of COVID-19 convalescent plasma in emergency room patients with mild to moderate symptoms of COVID-19.Following a second planned interim analysis of the trial data, an independent d...
Cancer Genetics (CGIX) +131%.The OLB Group (OLB) +83% on plan to offer Cryptocurrency payment options via blockchain technology.BioHiTech Global (BHTG) +66%.Bio-Path Holdings (BPTH) +50%.Neptune Wellness Solutions (NEPT) +48% on acquisition of organic baby food maker Sprout Foods.Ga...
News, Short Squeeze, Breakout and More Instantly...
Liminal Biosciences Inc Company Name:
LMNL Stock Symbol:
NASDAQ Market:
Liminal Biosciences Inc Website:
Evotec SE (EVO) is expected to report $-0.03 for Q3 2023 Amplifon (AMFPF) is expected to report for Q3 2023 Compass Therapeutics Inc. (CMPX) is expected to report $-0.11 for Q3 2023 Astronics Corp. - Class B (ATROB) is expected to report for Q4 2023 Charge Enterprises Inc. (CRGE) ...
Liminal BioSciences Inc. (LMNL) is expected to report for Q3 2023
LIMINAL BIOSCIENCES ANNOUNCES COMPLETION OF THE PLAN OF ARRANGEMENT WITH STRUCTURED ALPHA LP Canada NewsWire LAVAL, QC and CAMBRIDGE, England , Sept. 26, 2023 /CNW/ - Liminal BioSciences Inc. ("Liminal BioSciences" or the "Company") is pleased to announce tha...